Lens Usa

Acri.LISA (R) Lens – a surgical advance visionary Carl Zeiss – Revolutionizes the existing technology

Multifocal intraocular lenses (IOLs) are the most exciting advance in cataract and presbyopia corrective surgery in 25 years to meet the expectations of a growing population fighting for an active life with a minimum glasses or no support.

The mission in recent years has been to provide a surgical application for multifocal vision correction. Patients who wanted to improve their quality of life and the surgeons wanted a product with a predictability of the outcome of the vision and patient satisfaction of high.

Dr. Christoph Kranemann, a leader in ophthalmology, laser eye surgery and cataract and glaucoma surgery complex, was the first surgeon in Spain to offer a remarkable new surgical solution. "I chose the Acri.LISA (R) lens design because it is less likely to give patients any unwanted party effects. Comparatively, it was a challenge to give people a fast and intermediate vision using the same lens in both eyes. "

First patient of Dr. Kranemann's is Hannelore, a woman of 63 years. She had worn glasses since adolescence, but from their first 50 was with a rapid decline in their vision. Hannelore said, "I was constantly need new glasses because my vision was changing every few months, and to make matters worse, each eye needs a different correction. It was not unusual for me to carry several pairs of glasses for different tasks such as reading – often blurred, walking, using the computer and driving. Night driving was not possible and was limited in my normal activities, always trying to keep my ability to see. "condition Hannelore is not uncommon and Acri.LISA (R) lens was designed to allow patients to see up close distance and in between without relying on a collection of glasses. Hannelore recalled, "I had my first eye operated Oct.2nd, 2008. I was very anxious, but very hopeful. To my amazement, I could see clearly immediately right after the surgery and the next day I saw things I never could. "

Dr. Kranemann, satisfied with the results, noted that there had "negative symptoms post-op. Second surgery was performed in the same month of 30 October 2008. Detail, "There are limitations with other technologies, including halos and starbursts – particularly in the first six months, ended a challenge for a mix and match systems perspective to address within walking distance and intermediate vision. Hannelore was thrilled. "It was a miracle, and although my eyes were two different problems of vision, now I have need for any glasses at all. I can even see the eyebrows start. My life has totally changed. I feel independent. I can even drive at night. "

Dr. Kranemann declared, "the most significant difference post-op was true responses of patients of ecstasy and has no reported negative symptoms of any type. I hope to use this product more often and I think Acri.LISA (R) lens is certainly very promising. "Dr. Kranemann continue to achieve long term data to assist their initial results and plans to present his findings on Acri.LISA (R) of the target to their peers in various upcoming meetings of the Societies Ophthalmology. Acri.LISA (R) —

Improving the Quality of Life Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), listed on the TecDAX of Deutsche Boerse, is one of the leading global medical technology. The company provides innovative technologies and solutions-oriented applications that allow physicians to improve the quality of life of their patients. The company offers complete solutions, including implants and supplies, to diagnose and treat eye diseases. In the field of Neuro / ENT surgery company provides innovative visualization solutions. Medical technology portfolio of Carl Zeiss Meditec is completed with promising future technologies such as intraoperative radiation therapy.

From the company around 2,100 employees generated revenue of around EUR 600 million in fiscal year 2007/08 (ended September 30). The Carl Zeiss Meditec headquarters are in Jena, Germany. In addition to other subsidiaries in Germany, The company is represented by more than 50 percent of its employees at sites in the U.S., Japan, Spain and France. Thirty-five percent of the shares in Carl Zeiss Meditec are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the leading bands in the world participate in the electronics industry optics and optoelectronics.

The five business segments independent management of Carl Zeiss AG operate in the future market-oriented Medicine Research and Solutions, "Industrial Solutions" and "Lifestyle Products." Carl Zeiss AG is headquartered in Oberkochen, Germany. During the year 2007/08 (ended 30 September), the company generated revenues of around EUR 2.7 million. Carl Zeiss has approximately 13,000 employees in over 30 countries, including more than 8,000 in Germany.

For further information: Media Contact: For more information or to arrange an interview with Dr. Kranemann please Contact: Sandra Freer, SDA Communications (416) 239-0781, info@sdapublishing.com; Acri.LISA (R) Lens – Carl Zeiss Canada Ltd., Toronto, Ontario

About the Author:

Article Source: ArticlesBase.com – Acri.LISA(R) Lens – a Visionary Surgical Advancement from Carl Zeiss – Revolutionizes existing technology

Football US Orleans vs RC Lens end